This company has been marked as potentially delisted and may not be actively trading. NASDAQ:KMPH Zevra Therapeutics (KMPH) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Zevra Therapeutics Stock (NASDAQ:KMPH) 30 days 90 days 365 days Advanced Chart Get Zevra Therapeutics alerts:Sign Up Key Stats Today's Range N/A50-Day Range$4.48▼$6.2752-Week Range N/AVolume64,100 shsAverage Volume189,500 shsMarket Capitalization$200.47 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL. Read More Receive KMPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zevra Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KMPH Stock News HeadlinesZevra Therapeutics’ Earnings Call: Optimism Amid ChallengesAugust 15, 2025 | msn.comZevra Therapeutics Crashes, Reversing 89% Run. Why It Could Be An 'Overreaction.'August 14, 2025 | msn.comWashington prepares for warWhile the headlines obsess over overseas conflicts, Washington has been quietly preparing for something much bigger here at home. Emergency powers are being invoked, trillions are being mobilized, and the scale rivals anything we’ve seen since WWII. According to Porter Stansberry and Jeff Brown, a new economic arms race is already underway — one that could reshape markets, redirect capital, and impact billions of lives. They’ve just released an urgent briefing that explains what’s really happening behind the scenes, and which companies are positioned to benefit most.September 3 at 2:00 AM | Porter & Company (Ad)Zevra Therapeutics Inc options imply 12.4% move in share price post-earningsAugust 12, 2025 | msn.comZevra Therapeutics reports Q2 EPS $1.21, consensus $1.38August 12, 2025 | msn.comA Look at Zevra Therapeutics's Upcoming Earnings ReportAugust 11, 2025 | benzinga.comHere's Why 'Trend' Investors Would Love Betting on Zevra Therapeutics (ZVRA)July 15, 2025 | msn.comHC Wainwright & Co. Initiates Coverage of Zevra Therapeutics (ZVRA) with Buy RecommendationJuly 2, 2025 | msn.comSee More Headlines KMPH Stock Analysis - Frequently Asked Questions How were Zevra Therapeutics' earnings last quarter? Zevra Therapeutics, Inc. (NASDAQ:KMPH) posted its earnings results on Wednesday, March, 30th. The specialty pharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.08). Zevra Therapeutics had a negative trailing twelve-month return on equity of 16.12% and a negative net margin of 328.56%. When did Zevra Therapeutics IPO? Zevra Therapeutics (KMPH) raised $60 million in an initial public offering (IPO) on Thursday, April 16th 2015. The company issued 4,600,000 shares at $12.00-$14.00 per share. Cowen and Company and RBC Capital Markets acted as the underwriters for the IPO and Canaccord Genuity and Oppenheimer were co-managers. What other stocks do shareholders of Zevra Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Zevra Therapeutics investors own include Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Meta Platforms (META), SCYNEXIS (SCYX), BioCryst Pharmaceuticals (BCRX), Zoom Communications (ZM) and TherapeuticsMD (TXMD). Company Calendar Last Earnings3/30/2022Today9/03/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:KMPH CIK1434647 Webwww.kempharm.com Phone(321) 939-3416Fax319-665-2577Employees22Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.56 million Net Margins-328.56% Pretax Margin-335.26% Return on Equity-16.12% Return on Assets-14.17% Debt Debt-to-Equity Ratio0.14 Current Ratio10.10 Quick Ratio10.10 Sales & Book Value Annual Sales$10.72 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow23.28 Book Value$3.63 per share Price / BookN/AMiscellaneous Outstanding Shares34,505,000Free Float34,125,000Market Cap$200.47 million OptionableOptionable Beta2.16 Social Links 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:KMPH) was last updated on 9/3/2025 by MarketBeat.com Staff From Our PartnersHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredThis Coin Could Explode, and it’s Hiding in Plain Sight!The #1 coin with skyrocket potential right now... Sometimes the biggest opportunities are hiding in plain s...Crypto 101 Media | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zevra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zevra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KMPH Stock Alerts